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Abstract
Background: Monoclonal antibodies to Plasmodium lactate dehydrogenase (pLDH) have been previously used to
format immunochromatographic tests for the diagnosis of malaria. Using pLDH as an antigen has several
advantages as a sensitive measure of the presence of parasites within patient blood samples. However, variable
results in terms of specificity and sensitivity among different commercially available diagnostic kits have been
reported and it has not been clear from these studies whether the performance of an individual test is due simply
to how it is engineered or whether it is due to the biochemical nature of the pLDH-antibody reaction itself.
Methods: A series of systematic studies to determine how various pLDH monoclonal antibodies work in
combination was undertaken. Different combinations of anti-pLDH monoclonal antibodies were used in a rapid-
test immunochromatographic assay format to determine parameters of sensitivity and specificity with regard to
individual Plasmodium species.
Results: Dramatic differences were found in both species specificity and overall sensitivity depending on which
antibody is used on the immunochromatographic strip and which is used on the colorimetric colloidal-gold used
for visual detection.
Discussion: The results demonstrate the feasibility of different test formats for the detection and speciation of
malarial infections. In addition, the data will enable the development of a universal rapid test algorithm that may
potentially provide a cost-effective strategy to diagnose and manage patients in a wide range of clinical settings.
Conclusion: These data emphasize that using different anti-pLDH antibody combinations offers a tractable way to
optimize immunochromatographic pLDH tests.
Background
Rapid tests for the diagnosis of malaria offer the poten-
tial to accurately detect and follow malaria infections in
patients who live in remote areas without access to
modern medical clinics. These tests use a wicking strip
with immobilized antibodies to a particular antigen.
Infected blood is wicked up the strip and the presence
of the antibody-captured antigen is revealed with a
coloured bead or colloidal gold, which is conjugated to
a second antibody that also binds the antigen of interest
[1,2].
Most currently commercially available malaria diag-
nostic rapid tests are based on the detection of either
Plasmodium falciparum HRP2 protein or Plasmodium
lactate dehydrogenase (pLDH) [3-5]. HRP2 tests are lim-
ited to the detection of P. falciparum while pLDH-based
tests can detect multiple species of malaria parasites.
The performance and potential benefit of such tests has
been established for some time, but deploying such
technology effectively remains a challenge. Scores of stu-
dies to evaluate the performance of malaria rapid diag-
nostic tests have been conducted [3-5]. While the
general consensus has emerged that they perform well
collectively, results have varied and have led investiga-
tors to a wide range of conclusions about the validity
and utility of rapid tests. One of the largest potential
causes of variability is the source of the rapid test itself.
Currently, there are dozens of tests available from a
variety of manufacturers. While efforts to systematically
evaluate their quality have been instigated by WHO [6],
more can be done to accurately define the performance
characteristics and capabilities of these tests and to
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targeted by these tests.
One advance would be to better understand how the
targeted antigens are recognized by the antibodies used
in the commercially available tests. For instance, a mole-
cular characterization of HRP protein in P. falciparum
has identified variability in the number and type of histi-
dine-rich repeats within HRP2 [7,8]. In addition, histi-
dine-rich repeats are found in other P. falciparum
proteins that could potentially cross react with antibo-
dies directed to HRP2. Establishing what type of histi-
dine repeats are recognized by antibodies used in rapid
tests and matching those data with test performance
would be an important denominator to help provide
accurate comparisons of test performance and predict
their utility. Most commercially available HRP2 based
tests rely on a single monoclonal antibody but can also
incorporate polyclonal antibodies. So far, the empirical
specificity of such reagents has not been systematically
examined.
A panel of monoclonal antibodies directed to Plasmo-
dium-LDH has been previously developed [1,9,10].
These antibodies show different specificities to the four
species of malaria parasites that typically infect humans.
Moreover, some of these antibodies have been incorpo-
rated into commercially available tests. It was found
that differences in the combination of antibodies can
have dramatic effects on the performance capabilities of
a rapid test. These effects encompass changes in both
specificity and sensitivity. Presented here is a thorough
empirically derived matrix for how the pLDH antibodies
perform in combination within the rapid diagnostic for-
mat. These results emphasize that variability among
commercially available tests could come from different
formulas of antibodies used and that with proper atten-
tion, optimizing this parameter may lead to better tests.
In addition, these data support the proposal of new test
formats that can sequentially diagnose malaria with
high sensitivity and then uniquely identify which Plas-
modium species is/are present within infected blood.
This latter step might not only identify blood infected
with individual species of Plasmodium malariae, Plas-
modium vivax, Plasmodium falciparum,o rPlasmodium




Test strips were made according to previous studies [1].
All antibodies were adjusted to 1 mg/ml in PBS prior to
striping at 1 μl/cm. Antibodies were striped onto Milli-
pore nitrocellulose membranes using a CAMAG striper
(Muttenz, Switzerland).
Running buffer
The buffer used to run the test strips and dilute the
pLDH enzymes was 100 mM Na Borate (pH 8.), 1% Tri-
ton X-100, 1% Lactose, 1% Casein. Reagents were pur-
chased from Sigma (St. Louis, MO), except for the
Hammersten grade casein that was purchased from
BDH (Poole, UK).
Gold conjugates
Fresh solutions of trisodium citrate (1%) and Gold
chloride (1%) were filtered through a 0.2 micron filter.
One ml of gold chloride solution was added to purified
water (100 mls) stirring in an acid washed 250 ml Erlyn-
meyer flask. The solution was brought to a slow boil
and then added to it was 12 mls of the trisodium citrate
solution. The solution was kept at a low boil until pink,
after which 8.4 mls of the 1% gold choride solution was
added to yield a dark purple gold colloid. The solution
was maintained at a boil until the colloid matured to a
purple-reddish color. Heat was removed and the colloi-
dal solution stirred for an additional 15 min. The result-
ing solution yielded a colloidal gold measuring an
optical density of 10 at 530 nm.
To conjugate the colloidal gold a 50 ml conical poly-
propylene tube was used to serially mix 2 mls of 0.1
Tris base pH 8.3, 2 mls of monoclonal antibody at 100
μg/ml previously dialyzed in 5 mM HEPES pH 6.5. 10
mls of colloidal gold solution was then added to the
conical tube and mixed at 25°C for 5 min. 2.5 mls of
Running Buffer lacking Triton X-100 was then added
and mixed for an additional 5 min.
Recombinant pLDH
Recombinant pLDH isoforms for Plasmodium falci-
parum (Pf-LDH), Plasmodium malariae (Pm-LDH),
Plasmodium ovale (Po-LDH) and Plasmodium vivax
(Pv-LDH) were made as previously described [1,9].
Crude lysates of Escherichia coli induced to express
pLDH isoforms were used as the source of antigen. The
sequence previously described for Plasmodium knowlesi
LDH [10] was used to construct a synthetic gene engi-
neered for expression of Pk-LDH in Escherichia coli.
Enzyme activity was measured by the conversion of
APAD and Lactate to APADH and Pyruvate as pre-
viously described [9,11,12]. Enzyme activity was adjusted
to 100 μM -min - ml to make comparable lysates stocks,
which were stored at -80°C in 5% glycerol in aliquots of
20 μls. For P. falciparum pLDH, this level of activity is
roughly equal to a blood sample containing 5 × 10
7
parasites/μl or 1000% parasitaemia (10 parasites per red
blood cell). This calculation is based on estimates from
in vitro grown infected red blood cell cultures with an
estimated 10% parasitaemia wherein it was found that
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-min -ml. Previous biochemical studies on purified
recombinant pLDH demonstrated that the all human
Plasmodium species show a specific activity of ~1000
μmol -min-mg for the conversion of APAD to APADH
in the presence of lactate [9,11], a value ~5 fold higher
than conversion of NAD to NADH owing to the greater
Kcat for the APAD coenzyme. Using this as a basis for
calculation, the estimation method used here predicts
that a 10 μl sample of infected whole blood at 1% para-
sitaemia (equivalent to 50,000 parasites/μl) will have 1
ng pLDH. This estimate is in line with independent stu-
dies based on ELISA assays using commercially available
enzyme standards and cultured parasites where it was
estimated that a 10 μl sample of 1% parasitaemia con-
tains 0.3 ng pLDH [13].
Immunochromatographic assay
Enzyme dilution samples (10 uls) were made in 96 well
polystyrene plates. 2 drops of running buffer were added
to each well as well as 10 μls of gold-antibody conjugate.
Test strips were inserted into the wells and allowed to
wick the sample for 10 min. Strips were then moved to
a fresh well containing 4 drops of running buffer and
allowed to clear for 10 min before being read. Strips
were air dried prior to photography.
Immunocapture pLDH assay
The immunocapture assay was based on previously
described pLDH immunocapture assay [1]. Polystyrene
ELISA plates were incubated with 200 uls of goat-anti-
mouse affinity purified antibody at 0.1 mg/ml in PBS
overnight. Wells were washed three times in PBS and
then incubated with monoclonal antibody diluted in
PBS containing 1 mg/ml BSA. Monoclonal antibodies
were allowed to bind for 2 hrs. Wells were washed three
times in PBS and then incubated with a solution of
recombinant enzyme (diluted 1:20 from stock in run-
ning buffer) for 1 hr. Wells were then washed three
times in PBS and reacted with 0.1 M Tris pH 9.0, 1 mM
APAD, 100 mM Lactate 0.2% Triton X-100, 0.3 mM
Nitroblue tetrazolium, 0.1 mg/ml Diaphorase and moni-
tored spectrophotometrically for the production of for-
mazan salt at 585 nm.
Results
Antibodies to pLDH
Previous studies have characterized monoclonal antibo-
dies to pLDH. These efforts were continued to produce
a comprehensive panel of stable monoclonal cell lines
that produce reliable antibodies that react strongly with
pLDH without reacting with human LDHs [1]. Their
specificity was first evaluated in an enzyme capture
assay (Figure 1). Each monoclonal antibody was
immobilized in an ELISA plate, and recombinant LDH
was allowed to bind to the antibody. Unbound pLDH
was washed away and bound pLDH was assayed by
monitoring the conversion of Lactate and NAD to pyru-
vate and NADH. Importantly, each antibody was able to
capture active pLDH demonstrating that the epitopes
recognized were localized to the enzyme surface. These
results also showed remarkable specificity with the abil-
ity of some antibodies to distinguish pLDH from differ-
ent species of malaria. So called “pan” antibodies, which
recognized all pLDH species, included 1E9, 6C9, 14C2,
and 15F10. Plasmodium falciparum-specific antibodies
included 7G9 and 17E4. Antibodies that exclusively cap-
tured P. vivax LDH included 11D9 and 13H1; antibodies
reactive with only P. ovale were 4H10 and 10D12.
Other antibodies showed a mixed set of specificities.
For instance, 19G7 reacted with all pLDH isoforms with
the exception of P. ovale. This antibody was incorpo-
rated into the original OptiMAL assay, which utilized
two capture lines [1]. One utilized 17E4, a P. falciparum
specific antibody, and 19G7 to detect P. falciparum as
well as additional species. This test was found not to
recognize P. ovale infections [14] as confirmed here by
the inability of the 19G7 to recognize recombinant P.
ovale LDH in the capture assay. The specificity profile
of 19G7 within the capture assay is shared by the
V O  M F K 
1E92C4 ++ ++  ++ ++ ND 
2B5AC12A3 ++ +/-  ++ ++ ++ 
4H105A3 - ++  -  - ND 
5E7ED11AC3 - -  ++  ++  +/- 
6C9D6G2 ++ ++ ++ ++ ++ 
7G9G1 ++ ++ 
6E7CF10 - -  ++  ++  - 
7E7 - -  ++  +/-  - 
9C1BG6 - ++  ++ -  - 
10D121C10 -  ++  - - - 
11D9AC6 ++ - -  - ++ 
12G12AB7 ++ ++ ++ ++ ++ 
13H11AC9CE5 ++ - -  - ++ 
14C25G4 ++ ++ ++ ++ ++ 
14G33B9 ++ ++  ++ ++ ND 
15F102H11 ++ ++ ++ ++ ++ 
17E4D6 - -  -  ++  ++ 
19G7C10 ++  -  ++ ++ ++ 
20G7BA5 ++ ++  ++ +/- ++ 
10F9CF3 ++ ++  ++ ++  ND 
Figure 1 Enzyme pLDH capture assay. The indicated antibodies
tested in an immune-capture ELISA format for the ability to
immobilize pLDH. Captured enzyme activity was assessed by the
conversion of lactate and NAD to pyruvate and NADH. Results were
then graphically condensed to indicate none (-) strong (++), or very
weak (-/+) captured enzyme activity.
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Page 3 of 14additional antibody 2B5. The antibody panel also has
antibodies that bind to both P. malariae and P. falci-
parum LDH but do not bind P. vivax or P. ovale LDH.
These include antibodies 7E7 and 6E7. Additional
experiments showed the of reactivity of the 7E7 anti-
body to be much stronger for P. malariae than for P.
falciparum LDH which could be potentially exploited by
using different buffer conditions to bias reactivity
enough to make 7E7 a P. malariae-specific antibody.
While the ratio of reactivity of 7E7 to P. malariae LDH
and P. falciparum LDH could be increased in explora-
tory studies by adjusting constituents in the buffer, a set
of assay conditions that excluded all reactivity of 7E7 to
P. falciparum LDH could not be found. Thus, no anti-
body was found that had exclusive specificity towards P.
malariae LDH.
Other antibodies showed different repertoires of reac-
tivity. For instance, 20G7 reacts strongly with P. malar-
iae, P. ovale,a n dP. vivax but only very weakly with P.
falciparum LDH, theoretically making it possible for this
antibody to differentiate all non-falciparum infections if
optimized correctly. The 6E7 and 9C1 antibodies were
strongly reactive towards P. malariae LDH, the former
also reacting with P. falciparum LDH and the latter also
reacting with P. ovale LDH. In principle, the reaction
profile of 6E7 and 9C1 might provide the tools to
uniquely detect P. malariae infections. Although both
antibodies cross react with other pLDH species, the only
species they both bind is P. malariae. Thus a rapid test
with a capture line of 6E7 and a reporter bead coated
with 9C1 theoretically would form a positive reaction in
the presence of P. malariae LDH.
Placement of epitopes
Two pLDH structures from human malarias have been
solved by X-ray crystallography [15,16]. Both are of the
native tetrameric form of the enzyme and highly similar.
These structures were used to map which surface
exposed residues might account for the species differ-
ences in antibody reactivity (Figure 2). Surprisingly,
these differences were scattered across the surface of
pLDH and did not focus to large discrete patches. Thus,
the epitope differences that determine differential bind-
ing of various antibodies are likely to be small, perhaps
1-2 amino acid differences as determinants of species
specificity.
Rapid test combinations
Next examined was how the antibodies performed in an
immunochromatographic test format. These tests have
two components: one is the nitrocellulose strip that has
an antibody solution stripped across it to make a band
where pLDH can be immobilized; the other is a colloidal
gold antibody conjugate which is immobilized on the
strip in the presence of a bridging antigen. Successful
capture of the gold conjugate on the antibody stripe
requires that the two antibodies used in the test bind to
different non-competing epitopes.
It was first tested whether antibody on the gold conju-
gate made a difference with regard to sensitivity (Figure
3). Test strips were made with the P. falciparum-specific
antibody 17E4 and reacted in the presence of recombi-
nant P. falciparum-LDH in combination with colloidal
gold conjugates made with 6C9, 12G1, or 19G7 antibo-
dies. The antibodies used in the gold conjugate all react
strongly with Pf-LDH in the antibody capture assay (Fig-
ure 1), yet differences were found with regard to their
sensitivity when used on the colloidal gold. Namely, the
6C9-gold and the 12G1-gold gave stronger signals with
lower amounts of pLDH than did the 19G7 gold conju-
gate. These results indicate that sensitivity of a particu-
lar malaria rapid test format might be optimized by
using different antibody colloids.
A comprehensive examination was then conducted to
determine how each antibody combination would work
in the immunochromatographic format (Figure 4). A
colloidal gold antibody conjugate for each of the antibo-
dies was created. Importantly, a standard set of condi-
tions was used for making these conjugates to facilitate
comparison. However, it is known that differences in
buffer conditions during the conjugation procedure can
have effects on the quality of the resulting conjugate.
Thus, each of the antibody gold conjugates used in this
study still has the potential of being further optimized.
All of these gold conjugates were evaluated using strips
in which each antibody was striped. Recombinant pLDH
from P. falciparum (Pf), P. malariae (Pm), P. ovale (Po),
and P. vivax (Pv) was used for each test using a stan-
dard running and wash buffer. The enzyme was diluted
in running buffer to match the concentration of enzyme
estimated to be in a typical blood sample with a parasi-
taemia of 1%. This value was chosen as generally low
enough to indicate relative sensitivities of antibody com-
binations based on the intensity of the reaction band
and high enough to demonstrate the fidelity of the spe-
cificity for individual pLDH species isoforms.
In general, the antibody specificities determined in the
pLDH capture assays (Figure 1) were recapitulated in
the rapid test format (Figure 4). However, the relative
strength of the reaction line varied among the combina-
tions. Thus, some antibodies on the capture line were
well suited to particular partner conjugate antibodies
but not others. One antibody that worked very well in
combination with the P. falciparum and P. vivax specific
antibodies was 6C9, which to the knowledge of the
authors, is routinely conjugated to the colloidal gold
reporter in currently available commercial rapid malaria
pLDH tests.
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Page 4 of 14Figure 2 Hypothetical epitope surface of pLDH. Structures of Pf-LDH and Pv-LDH or predicted structures of Po-LDH and Pm-LDH determined
by molecular threading are shown in a computed chimeric pLDH tetramer where each of the 4 subunits is taken from the four human malarias.
Pf-LDH, red; Pv-LDH, green; Pm-LDH, cyan, Po-LDH, yellow. A. Shows ribbon structure of the pLDH tetramer. B. Shows the molecular surface of
the pLDH tetramer with surface-exposed residues unique to the different pLDH isoforms respectively indicated in black. C. Shows the molecular
surface and residues shared between Po-, Pm-, Pv-LDH but that are different from Pf-LDH are indicated in black. The indicated residues are
candidates for the epitopes of 9C1 and 20G1 antibody. D. Shows the pLDH tetramer with the heavy (red) and light (purple) chains of a typical
antibody FAB fragment. This is to show the relative scale of the molecules to demonstrate that an epitope could conceivably span patches
found in two different pLDH subunits.
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Page 5 of 14The matrix also tested how well a single antibody per-
formed when it was used on both the capture line and
reporter gold conjugate. In principle, this type of
approach should still allow the antigen to form a sand-
wich between the capture line and the reporter conju-
gate since pLDH is a tetramer and there could be four
epitopes per pLDH to allow for crosslinking. In some
cases, this approach worked well. For instance, the pan-
s p e c i f i ca n t i b o d y1 5 F 1 0g a v ear o b u s ts i g n a lf o ra l l
malaria species when used as both the capture and con-
jugate. For most antibodies, however, this approach
yielded only weak signals, indicating that competition
between the capture antibody and the conjugate anti-
body for the epitopes available on pLDH was formid-
able. This can be seen with antibodies such as 6C9 and
19G7. These are capable of yielding strong signals with
P. falciparum, P. vivax,o rP. malariae LDH when used
on either the capture or conjugate; however, when used
for both only a meager signal was achieved (Figure 4).
There were many instances where the performance of
a particular antibody combination differed from what
would be predicted from initial characterization by the
immuno-capture assay. For example, when the P. falci-
parum-specific antibody 17E4 was conjugated to gold, it
c o u l dn o wr e a c tw i t hP. vivax LDH immobilized by the
13H1 antibody and P. malariae LDH immobilized by
the 9C1 antibody. Similarly, when 11D9 and 20G7 were
used for the conjugate and stripe respectively, they
detected Pf-LDH even though neither of those antibo-
dies binds Pf- L D Hb yt h ee n z y m ec a p t u r ea s s a yn o rd o
they bind Pf-LDH with matched with other antibodies.
Importantly, when used as the capture antibody in com-
bination with the 6C9-conjugated gold, the 17E4, 13H1,
9C1, 11D9 and 20G7 antibodies all showed the specifi-
city profile that they had in the immunocapture assay,
suggesting that the antibodies may react differently
depending on the surface (test strip or gold conjugate)
to which they are immobilized. A similar characteristic
was found for the pan-specific antibodies 14C2 and
15F10. When they were immobilized on the strip, they
reacted strongly with a number of gold-conjugated anti-
bodies for all species of pLDH, and fit the predictions
from the immuno-capture assay. However, when conju-
gated to gold, 14C2 and 15F10 had extremely limited
reactivity both in terms of the repertoire of antibodies
on the test strip they could sandwich with as well as the
species of pLDH they could react against. These data
emphasized that the rapid test formulation could not be
completely predicted from the capture data alone.
Specific detection of P. falciparum
Two antibodies (17E4 an 7G9) showed excellent specifi-
city detecting Pf-LDH while not binding Pm-LDH, Po-
LDH, or Pv-LDH (Figure 5A). The experiment shown
used high concentrations of pLDH, levels that would
exceed that in a theoretical patient sample of 100%
parasitaemia. Figure 5B shows that a range of Pf-LDH
concentrations, starting at levels in excess of that esti-
mated in a sample of 100% parasitaemia, reacted
strongly with 17E4 antibody but did not react at all with
the P. vivax-specific 13H1 antibody. These results
demonstrate high fidelity of particular antibodies for
particular isoform species of pLDH and diminish the
likelihood that antigen cross-reactivity explains observa-
tions of non-specificity between Pf and Pv reported for
some patient samples analyzed by commercial malaria
rapid tests that incorporate 13H1 or 11D9 antibodies
[17].
Of the Pf-specific 17E4 and 7G9 antibodies, many of
the earlier versions of pLDH tests used in clinical stu-
dies incorporated 17E4. The high specificity of these
antibodies is restricted to their use as the immobilizing
antibody on the test strip; as noted above some loss of
specificity was observed when 17E4 was used instead on
the gold conjugate (Figure 4). Overall, both 17E4 and
7G9 have similar characteristics. Indeed, the epitopes for
7G9 and 17E4 largely overlap as determined by compe-
tition experiments (Figure 5C). Here, both 7G9 and
17E4 as well as two pan-specific antibodies 14C2 and
15F10 were stripped onto the nitrocellulose strips.
These strips were then reacted with Pf-LDH and 19G7-
conjugated gold in the absence and presence of excess
unbound antibodies. In the absence of excess competing
antibody all four striped antibodies immobilized Pf-LDH
and the gold conjugate as expected. In the presence of
excess 19G7 all signals were inhibited because the free
19G7 bound its epitope on Pf-LDH and effectively com-
peted with the 19G7 on the gold conjugate. No compe-
tition was observed with excess 13H1, which is specific
Figure 3 Sensitivity of detecting P. falciparum LDH as a
function of antibody gold conjugate. Test strips with
immobilized 17E4 antibody specific for Pf-LDH were used to test for
reaction to Pf-LDH. The dilution series (1:10) started with a pLDH
solution diluted 1:100 from the stock solution to produce a sample
solution estimated to represent a 10% parasitaemia. Tests were
visualized with colloidal gold conjugated to the indicated
antibodies.
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Page 6 of 14Figure 4 Rapid Test Reaction Matrix. Left: Reactivity of various species of pLDH in the enzyme capture assay is shown for comparison. Right:
The antibodies indicated in the Y-axis were conjugated to colloidal gold under standard conditions and used to test for reactivity with
recombinant pLDH of P.falciparum, P. vivax, P. malariae, and P. ovale. Each enzyme conjugate was used with a test strip containing the indicated
antibodies (X-axis) immobilized on the test strip. Line intensity of each reaction was color coded as a function of its intensity according the
scheme indicated in the inset legend. The pLDH enzyme solution mimicked a sample of 1% parasitaemia.
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Importantly, excess 17E4 effectively competed away
both the 17E4 band as well as the 7G9 band. Similarly,
excess 7G9 competed away both the 7G9 band and the
17E4 band, indicating that 7G9 and 17E4 compete for a
similar epitope on the surface of Pf-LDH. Both antibo-
dies also show comparable sensitivity. This was revealed
in a titration series (Figure 5D), where Pf-LDH was seri-
ally diluted and tested against strips with both 17E4 and
7G9 using the pan-specific 6C9-gold conjugate. These
experiments revealed both antibodies gave similar band
intensities across a broad concentration of Pf-LDH
samples. Although 17E4 and 7G9 have similar perfor-
mance overall, there are subtle differences between
these two antibodies. This is important because those
subtle differences might have large effects with regard to
optimizing a final commercial rapid malaria test. For
instance, when 7G9 and 17E4 are used on the test strip,
the 7G9 stripe formed a much more intense band than
17E4 when used against gold conjugated to 2B5 or 10F9
(Figure 4). Also, the unexpected reaction of Pf-LDH
with 11D9-conjugated gold (ostensibly Pv-specific) and
immobilized 17E4 was not observed with immobilized
7G9 in combination with 11D9-gold (Figure 4).
Pan-specific antibodies
Antibodies that recognize all species of pLDH are
important components for a pLDH rapid test. Earlier
versions of pLDH-based tests used two “pan” specific
antibodies. The 6C9 antibody was used as the gold con-
jugate and the experiments here confirm that this con-
figuration performs very well in terms of both sensitivity
and specificity. The 19G7 antibody used in older tests
was initially used as the immobilized pan specific anti-
body that would form a band with both Pf-LDH and
other pLDH isoforms. Subsequent studies, however,
showed that the 19G7 antibody does not recognize Po-
LDH. The expanded panel of monoclonal antibodies
reveals additional pan antibodies. In the pLDH enzyme
capture assay, 14C2 and 15F10 recognize all forms of
pLDH and thus are comparable to 6C9; the 2B5 anti-
body behaves like 19G7 in that it captures Pf-, Pm-, and
Pv-pLDH isoforms but fails to robustly capture Po-LDH.
Experiments to determined how distinct the correspond-
ing epitopes for these antibodies were conducted using
the competition assay described above (Figure 5E). Here
it was found that 2B5 does not compete with 19G7,
14C2, or 15F10 suggesting that 2B5 indeed has a differ-
ent epitope than the 19G7 and the others. Also, it was
found that 6C9, which robustly binds all species of
pLDH does not compete with 14C2 and 15F10, which
also bind all species of pLDH. Thus, these results have
identified two pairs of true pan-specific antibodies
(6C9:14C2 and 6C9:15F10) that complement each other
-rather than compete–for pLDH binding. This is impor-
t a n ts i n c ei tm a yn o wb ep o s s i b l et om a k eas i n g l et e s t
line capable of detecting all species of human malaria
parasites. Such a test would be expected to be quite sen-
sitive since it uses two non-competing antibodies on the
test line and gold conjugate respectively, thus avoiding
the inhibitory competition effect observed when a pan-
specific antibody is used on both the test strip and gold
conjugate. Figure 4 supports this prediction as these
combinations yield some of the most intense bands
found within the systematic matrix comparison.
Figure 5 Specificity of epitopes. A. Test strips with immobilized
7G9 and 17E4 were reacted with high levels of pLDH from the
indicated species (1:10 dilution of stock enzyme to mimic a > 100%
parasitaemia). Immunoreactive bands were visualized with 6C9-
conjugated colloidal gold. A control (Cont) line comprised of goat
anti-mouse antibody is also shown. B. Test strips with 13H1 and
17E4 were reacted with a serial dilution (1:10) of Pf-LDH where the
starting concentration represented a > 100% parasitaemia. C.
Competition experiment to demonstrate epitope differences and
similarities. Prior to wicking up the strip, the Pf-LDH sample was
incubated with buffer (ø) or buffer containing excess 17E4, 7G9,
19G7, or 13H1 antibodies as indicated at a final concentration of
200 μg/ml for 2 min. D. A serial dilution (1:10) titration of Pf-LDH
was analyzed on test strips with immobilized 7G9 and 17E4. Bands
were visualized with 6C9-conjugated colloidal gold. E. Test strips
with immobilized 14C2 and 15F10 were reacted with Pf-LDH and
19G7-conjugated colloidal gold. The Pf-LDH samples were
preincubated with buffer alone (ø) or free 6C9, 2B5, or 19G7
antibody for 2 min prior to analysis.
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Page 8 of 14Differentiation of four human malarial parasites
The matrix of antibody combinations (Figure 4)
revealed several combinations with selectivity for dif-
ferent malaria species. This allowed us to format a
number of test prototypes that combine high sensitiv-
ity with the ability to discriminate different species.
Figure 6A shows the ability to detect and differentiate
all four species of human malaria on a single test strip.
Here Pf-LDH is revealed with immobilized 7G9, Pm-
LDH is revealed with immobilized 7E7, Po-LDH by
10D12, and Pv-LDH by 13H1. A 6C9 conjugated to
gold was used for detection, which nicely yielded
unique single lines for each pLDH isoform. The 7E7
antibody was used as the Pm-specific antibody; how-
ever, 7E7 can react at higher concentrations of Pf-LDH
(Figure 6B). Thus, while most P. falciparum infections
are likely low enough not to cause this cross-reactivity,
av e r yh i g hPf parasitaemia may give a false-positive
Pm reaction in such a format. Even with this limita-
tion, optimization of the gold conjugate, running
buffer, and other parameters may eliminate this com-
plication in a finished test. Alternatively, a set of strips
using different gold conjugate antibodies could be used
to avoid this cross-reactivity (see below).
The experiments also showed that the 20G7 antibody
did not react or reacted extremely poorly with Pf-LDH
while giving strong reactions with Pm-, Pv -, and Po-
LDH. By co-striping 20G7 with 7G9, a test was made
that could differentiate P. falciparum-LDH from non-P.
falciparum LDH. Potentially, this format would be quite
useful for making the major differential diagnosis
required in the determination of malarial infection.
Moreover, it has an advantage over earlier pLDH based
tests that contain a Pf-specific and pan-specific line
since the Pf/non-Pf test (Figure 6C) can identify mixed
infections (eg Pf and Pv) while the Pf/pan test cannot.
Careful attention has to be paid to the type of antibody
combinations used for this format. For instance, a test
s t r i pw i t h7 G 9a n d2 0 G 7w o r k sw e l la saPf/non-Pf test
when used with 2B5-conjugated gold (Figure 6C). How-
ever, when the same test strip is used with 19G7-conju-
gated gold, the species selectivity is lost since 20G7 can
now react with Pf-LDH bound to 19G7-conjugated gold.
It is not clear how there is an apparent “gain” in binding
activity of the 20G7 antibody under these conditions.
However, it is likely that subtle changes in the surface
or conformation of pLDH that result from binding one
antibody may inhibit or promote binding of a second
antibody via a weak allosteric effect.
Figure 6E takes the Pf/non-Pf test a step further by
adding a 13H1 stripe to the test format. This format
could further confirm that the non-Pf species is P. vivax
b u tc o m e sw i t ht h ec a v e a tt h a tt h et e s tc a n n o td i s t i n -
guish a mixed Pv/Pm or Pv/Po infections. Such mixed
infection may be too rare to confound the effective use
of such a test however.
The antibody matrix also revealed an alternative com-
bination for making a Pf/non-Pf test using 7G9 and
9C1, respectively on the test strip (Figure 6F). This for-
mat reveals Pf-LDH reacts only on the 7G9 line; Pm-,
Po-, and Pv-LDH are only revealed on the 9C1 line.
Figure 6 Differentiating pLDH orthologs.A .T e s ts t r i p sw i t ht h e
indicated immobilized antibodies were reacted with recombinant
Pf-LDH, Pm-LDH, Po-LDH or Pv-LDH and visualized with 6C9-
conjugated colloidal gold. A goat anti-mouse line is also indicated
(Cont). A 1:100 dilution of enzyme (~ 10% parasitaemia) was used.
B. A dilution series (1:10) of Pf-LDH and Pm-LDH was reacted with
test strip containing immobilized 7E7 and 17E4 antibodies. The
starting concentration of enzyme approximates a blood sample of
10% parasitaemia. C. Example of a Pf/non-Pf test format that can
detect all four species of human malaria and distinguish Pf-LDH
from the other species. Test strips contained immobilized 20G7 and
7G9 antibodies as well as a control (Cont) goat anti-mouse line.
Reactions were visualized with gold conjugated to 2B5. A 1:100
dilution of the enzyme (~10% parasitaemia) stocks was used for the
samples. D. The same 20G7-7G9 strip used in C was used to detect
Pf-LDH using 19G7-conjugated colloidal gold. E. Similar assay format
as shown in C except with the addition of an immobilized stripe of
Pv-specific 13H1 antibody. F. Alternative Pf/non-Pf test format. Test
strips containing immobilized 7G9 and 9C1 were reacted with pLDH
from the indicated species. Reaction bands were visualized with
colloidal gold conjugated to either 6C9, 12G1, 14C2 or 15F10 as
indicated.
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well with a number of different antibodies conjugated to
gold including the 6C9 gold conjugate. The Pf/non-Pf
format using 7G9 and 9C1 was very strong and specific
for Pf, Pm,a n dPv;h o w e v e r ,Po reactivity was slightly
less than ideal. One way to optimize this reaction would
be to supplement the 20G7 line by mixing in the Po-
specific 10D12 or 4H10 antibody prior to striping to
make a mixed antibody line with stronger reactivity to
Po-LDH.
Specific detection of Plasmodium knowlesi
Plasmodium knowlesi (Pk) is ostensibly a primate
malaria. However, it can infect humans and cause a
high level of pathology due to its ability to create large
parasite burdens [18]. Earlier studies showed that Pk-
LDH binds to both the Pf-LDH specific antibodies 7G9
and 17E4 and also the Pv-specific antibodies 11D9 and
13H1 [10]. In an effort to find tools to discriminate Pk-
LDH from the four canonical human pLDH isoforms,
various combinations of antibodies for their ability to
react with Pk-LDH in the immunochromatographic
assay was assessed (Figure 7). These results confirmed
that Pk-LDH binds both 17E4 and 13H1 and addition-
ally revealed that Pk- L D Hd o e sn o tb i n dt h e9 C 1a n t i -
body (which does bind Po, Pv,a n dPm LDH isoforms).
Also, Pk-LDH did not bind the 6E7 antibody, which
is able to bind Pf, Pm,a n dPo-LDH. Thus, the discrimi-
natory power of using the 9C1 antibody in combination
with others would enable the design of a test format
that could better discriminate a P. knowlesi infection
from a P. vivax or P. falciparum infection. Humans
Figure 7 Differentiating P. knowlesi. A. Recombinant Pk-LDH was used in a immunochromatographic format matrix. The pLDH enzyme
solution was diluted to mimic a sample of 1% parasitaemia. B. Test strips with the indicated immobilized antibodies were reacted with Pf-LDH,
Pm-LDH, Po-LDH, Pv-LDH or Pk-LDH and 6C9-conjugated gold. The pLDH enzyme mimicked a sample of 10% parasitaemia.
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Page 10 of 14infected with P. knowlesi are typically misdiagnosed with
P. malariae when microscopy is used. Since the pLDH
reaction pattern of Pk-LDH is very different from that
of Pm-LDH (Figure 7B) the combined use of both RDTs
and microscopy would give a definitive differentiation
between P. malariae and P. knowlesi infection.
Discussion
It is clear from these studies that one pathway to opti-
mize pLDH diagnostic tests is to explore the use of
alternative antibodies that have slightly different binding
characteristics and which make use of the subtle anti-
genic differences on the surface of the pLDH enzyme.
Importantly, this is only one aspect for how to optimize
a finished commercially viable test since issues of stabi-
lity are also very important and formulations to achieve
optimal stability may differ for different antibodies. In
addition, the performance of the antibody combinations
used here could potentially be enhanced by optimizing
buffer conditions and solid support matrices used in the
test strip, as well as conditions for making the reporter
gold conjugates. The differences observed amongst the
different monoclonal antibodies demand a precise
approach to tailoring reagents, antibodies, and formats
in order to achieve consistent and robust test kits. This
may be best achieved by routine use of monoclonal anti-
bodies that have consistent reactivity characteristics
rather than by using polyclonal antibody mixtures that
yield a variable mix of antibody specificities that may
hamper reproducibility [19,20].
By mixing different monoclonal antibodies to pLDH, a
number of effective rapid malaria test formats could be
developed to meet the specific needs of particular clini-
cal settings. This strategy also provides means to
enhance the sensitivity and specificity of pLDH tests
over existing rapid test formats. Combining several
incremental improvements based on the observations
presented here may be enough to evolve a new series of
rapid tests that can meet a broad set of patient needs.
Given the success so far in the performance of some
pLDH tests, this pathway to improvement may make
widespread effective and commercially sustainable diag-
nostics a reality in a relatively short time. Hence an
extended search for more exotic biomarkers that face a
long period of experimental validation before being
employed in clinical practice as previously proposed [21]
may not be needed if minor improvements are made to
existing technology.
From the characterization of the antibody combina-
tions used here, a model is proposed for how new test
formats could be developed and eventually integrated
into a diagnostic algorithm that may be suitable for a
wide range of clinical conditions that span the whole
gamut of malaria prevalence (Figure 8). One format,
dubbed “Pan-modium“, contains a single line to indicate
the presence of malaria parasites in a blood sample and
uses two non-competing pan-specific antibodies. Pan-
modium would be comprised of 14C2 or 15F10 antibody
immobilized on the test strip and revealed by 6C9 con-
jugated gold. The Pan-modium strip would also contain
two control lines. One line would be an anti-mouse IgG
line, which would bind the gold-conjugate and serve as
a control to make sure the test reagents were correctly
w i c k e du pt h es t r i p .T h i st y p eo fc o n t r o ll i n es e r v e sa s
the industry standard for immunochromatographic tests.
The Pan-modium strip would also contain an additional
line and be comprised of normal mouse IgG (mIgG).
The mIgG line would not react with pLDH but would
react with anything in patient blood that could non-spe-
cifically link mouse antibodies together. Such non-speci-
fic activity has been noted before and can cause
apparent false-positives in pLDH tests [3-5,22]. By
including the mIgG line, the user would have the ability
to identify samples that have factors that cause such
false-positive reactions and allow the user to use alterna-
tive means or buffer additives to obtain a diagnosis.
Once a patient is diagnosed with a viable parasitaemia
in their blood with the Pan-modium strip, the clinician
could then use a different test termed “de-Linné-ate“,
dubbed in homage to the taxonomous Carl Linné (Lin-
neaus). The de-Linné-ate test would be formatted as a
pair of test strips (I and II). One would be striped with
the Po-specific antibodies 10D12 or 4H10; the Pv-speci-
fic 13H1 or 11D9; and the Pf-specific 17E4 or 7G9 anti-
bodies. When used in conjunction with 6C9 gold, this
test strip would uniquely identify Po, Pv,o rPf infections
or mixed infections of those species. A second (II) test
strip run in parallel would consist of 20G7 on the test
strip and 7E7 conjugated to gold. This combination only
reacts with Pm-LDH. By pairing 20G7 with 7E7, it
avoids the slight cross reactivity that 7E7 has with Pf-
LDH. This is because 20G7 does not readily bind Pf-
LDH. Thus, the only pLDH isoform to bind both 20G7
and 7E7 (and thus produce a line) is Pm-LDH.
Together, the pair of de-Linné-ate test strips, which
could be multiplexed together in a single device, would
give unambiguous identification of any and all species of
malaria parasites in an infected sample. The addition
the test could further be refined to also differentially
diagnose Pk. This could be done by reconfiguring the
de-Linné-ate-II strip to have immobilized 7E7 (a Pm
line) and 9C1 (a Po, Pm, Pv) line and reacted with 20G7
gold. Here the de-Linné-ate-I strip would show both a
“Pv“ and “Pf“ line but fail to give a 9C1 line in the de-
Linné-ate-II strip thus indicating a Pk infection rather
than a Pf/Pv mixed infection. In practice, however, the
addition of 9C1 into a five-test-line combination to dif-
ferentiate five species of malaria parasites may produce
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Page 11 of 14Figure 8 Proposed diagnostic algorithm. Model for how two different new test formats could be integrated into a uniform diagnostic
regimen. Initial diagnosis would be made using a pan-specific test termed Pan-modium. If the test were positive, a second test to determine the
species of malaria would be performed. This test, termed de-Linné-ate is comprised of 2 test strips (I and II) run in parallel. The de-Linné-ate strip
contains the indicated antibodies and uniquely identifies each of the four human malaria parasite pLDH orthologs. Once an anti-malarial drug
therapy has been initiated, progress towards clearing the malaria infection can followed using the all purpose Pan-modium strip.
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Page 12 of 14unneeded complexity for most clinical situations and
cause confusion.
Once the species of malaria has been correctly deter-
mined, an appropriate drug therapy can be chosen. To
follow the success of such therapy the clinician can
then follow up with repeated analysis using the Pan-
modium strip. Because pLDH levels closely correlate
with viable parasitaemia [1,23], successful drug therapy
results in loss of pLDH-test reactivity. If therapy failed
to reduce reactivity on the Pan-modium strip, the clini-
cian could confidently suspect a drug-resistant infec-
tion and change drug-therapy in response. In addition,
because the Pan-modium uses a single anti-malaria
antibody test line and could be adapted to a wide
range of clinical conditions, the potential of a widely
available, very low cost Pan-modium test that could be
economically produced on a massive scale would make
both the initial diagnosis and follow-up very affordable
and effective.
Conclusions
A panel of monoclonal antibodies against Plasmodium
lactate dehydrogenase can be used in various combina-
tions to uniquely identify all species of malaria parasites
that infect humans. In addition, different combinations
of antibodies were found to produce different levels of
sensitivity within an immunochromatographic rapid test
format. These results should help the development of
new diagnostic test kits with greater specificity, sensitiv-
ity and ability to differentiate among malaria parasite
species.
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